Thiazolidinediones Could Improve Endothelial Dysfunction and Risk of Premature Coronary Heart Disease in HIV-Infected Patients

Carrillo-Jimenez, Rodolfo; Lamas, Gervasio A.; Hennekens, Charles H.

doi:10.1177/107424840200700402

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As with metformin there has been evidence showing the benefits of the TZDs in improving insulin sensitivity, fat redistribution and specific CV metabolic indices in HIV lipodystrophy 22, 28. The potential benefits of TZDs, which promote differentiation of preadipocytes to adipocytes and redistributing fat from the viscera to subcutaneous tissue, suggested that they may be ideal agents in treating HIV lipodystrophy.…”

Section: Treatment Of Diabetes In Hivmentioning

confidence: 99%

Diabetes and HIV: the role of a specialist clinic

2005

View full text Add to dashboard Cite

The rising incidence of type 2 diabetes in the developed world is already well established. There are, however, specific populations in the occident where there is an increase in type 2 diabetes, but unrelated to obesity. One such group is the HIV infected population. Associated with this increase in diabetes, there has been a similar rise in cardiovascular disease. This review article aims to outline the aetiological factors that may precipitate diabetes and cardiovascular disease in this group, and establishes the role of a specialist diabetes and HIV clinic in the management of these individuals. Copyright © 2005 John Wiley & Sons, Ltd.

show abstract

Section: Treatment Of Diabetes In Hivmentioning

confidence: 99%

Diabetes and HIV: the role of a specialist clinic

2005

View full text Add to dashboard Cite

show abstract

“…Thiazolidinediones, PPAR gamma agonists may improve some of the features of HAART-induced dyslipidaemia and glucose intolerance including reduced circulating glucose, haemoglobin (Hb)A1c and triglycerides concentrations and raised HDL-cholesterol concentrations. 144 Another potential bene¢t is stimulation of peripheral blood mononuclear cells by PPAR gamma agonists such as rosiglitazone which inhibit HIV replication and reduce cytokine production such as TNF-alpha.…”

Section: Treatment Of Human Immunodeficiency Virus Related Dyslipidaementioning

confidence: 99%

The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment

Crook

2007

Ann Clin Biochem

View full text Add to dashboard Cite

This article was prepared at the invitation of the Clinical Sciences Review Committee of the Association for Clinical BiochemistryThe high global prevalence of human immunodeficiency virus (HIV) infection has been associated with high morbidity and mortality. The advent of highly active antiretroviral therapy (HAART) has, however, dramatically increased survival of patients infected with HIV. These patients now survive to develop metabolic complications of HIV infection and its treatment, including increased predisposition to atherosclerotic disease. HIV infection is normally associated with hypocholesterolaemia, hypertriglyceridaemia, low plasma HDL-cholesterol as well as alterations in other cardiovascular risk factors including inflammatory markers, clotting factors, homocysteine, apolipoproteins, lipoprotein (a), oxidative stress and non-esterified fatty acids. The use of HAART is, in particular, associated with dyslipidaemia and lipodystrophy with underlying insulin resistance and associated glucose intolerance. This article explores the metabolic abnormalities associated with increased cardiovascular risk that occur in HIV infection before and after antiretroviral therapy. The laboratory investigation and clinical management of HIVassociated dyslipidaemia and lipodystrophy will be discussed.

show abstract